p. 1985−1986
2476-762X
Vol.22/No.7
30 Kg/m2) (OR = 2.90, 95% CI 2.00- 4.21), and passive smoking (OR = 1.50, 95% CI 1.12- 2.02). Controversially, breastfeeding (OR = 0.37, 95% CI 0.23- 0.61) was protective factor in BC. Of non-modifiable risk factors for BC has reached menopause had the highest odds ratio (OR = 3.74, 95% CI 2.64- 5.29), followed by family history of BC (OR = 2.63, 95% CI 1.07-6.44) and age (≥ 40 years) (OR = 2.49, 95% CI 1.43-4.34). Conclusions: The most significant predictors of BC in Palestine were DM, hypertension, passive smokers, age (>40), reached menopause, and family history of BC. Almost all these risk factors are consistent with known risk factors for breast cancer in other parts of the world. ]]>
p. 1987−1995
2476-762X
Vol.22/No.7
p. 1997−2004
2476-762X
Vol.22/No.7
p. 2005−2009
2476-762X
Vol.22/No.7
p. 2011−2016
2476-762X
Vol.22/No.7
p. 2017−2024
2476-762X
Vol.22/No.7
p. 2025−2031
2476-762X
Vol.22/No.7
p. 2033−2041
2476-762X
Vol.22/No.7
p. 2043−2047
2476-762X
Vol.22/No.7
p. 2049−2052
2476-762X
Vol.22/No.7
1.25 than those who were Ki-67 expression negative (OR = 9.33, 95% CI= 2.07-42.18). However, no significant differences were observed between HER2 positive and HER2 negative groups. The optimized logistic regression model was TMB = -27.5 -1.82 ER – 0.73 PR + 0.826 HER2 + 2.08 Ki-67. Conclusion: Our findings revealed that TMB value can be predicted based on the expression level of ER, PR, HER-2, and Ki-67.]]>
p. 2053−2059
2476-762X
Vol.22/No.7
p. 2061−2067
2476-762X
Vol.22/No.7
p. 2069−2077
2476-762X
Vol.22/No.7
p. 2079−2087
2476-762X
Vol.22/No.7
p. 2089−2098
2476-762X
Vol.22/No.7
0.05) in different populations. The variants were detected using the PCR-RFLP method. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were determined by logistic regression models. Result: Significantly increased risk (p <0.05) were detected for both SNPs with CC (rs1801320- GC vs. GG: aOR=2.21, 95% CI=1.43-3.42; CC vs. GG: aOR=4.48, 95% CI=1.76-11.42; dominant model: aOR=2.49, 95% CI=1.65-3.76; recessive model: aOR=3.52, 95% CI=1.40-8.88; allele model: OR=2.30, 95% CI=1.63-3.26, and rs3218536- GA vs. GG: aOR=2.77, 95% CI=1.85-4.17; AA vs. GG: aOR=5.86, 95% CI=2.08-16.50; dominant model: aOR=2.97, 95% CI=1.99-4.42; recessive model: aOR=3.56, 95% CI=1.30-9.73; and allele model: aOR=2.21, 95% CI=1.62-3.00). Besides, older patients (>60 years) with rs1801320 showed significantly reduced risk (OR=0.53, 95% CI=0.29-0.96, p=0.04) but with rs3218536 depicted significantly increased risk (aOR=2.44, 95% CI=1.20-4.96, p=0.01) for CC. Conclusion: This study indicates an association of rs1801320 and rs3218536 polymorphisms with CC and confirms that patients older than 60 years are more likely to develop CC for rs3218536 polymorphism.]]>
p. 2099−2107
2476-762X
Vol.22/No.7
p. 2109−2115
2476-762X
Vol.22/No.7
p. 2117−2124
2476-762X
Vol.22/No.7
p. 2125−2134
2476-762X
Vol.22/No.7
7. For any fluorescence, the positive likelihood ratio was 2.34 (1.5, 3.65) and the negative likelihood ratio was 0.28 (0.13, 0.65). For distinct fluorescence, the positive likelihood ratio was 12.74 (3.18, 51.1) and the negative likelihood ratio was 0.43 (0.27, 0.68). There was moderate correlation between FNa and the other tests. Conclusion: Distinct fluorescence with FNa was very specific, low cost, and easy to perform and may contribute to confirm CIN2+ disease.]]>
p. 2135−2141
2476-762X
Vol.22/No.7
p. 2143−2152
2476-762X
Vol.22/No.7
p. 2153−2163
2476-762X
Vol.22/No.7
p. 2165−2169
2476-762X
Vol.22/No.7
p. 2171−2175
2476-762X
Vol.22/No.7
p. 2177−2184
2476-762X
Vol.22/No.7
0.05). However, results obtained by ΔΔCT method showed that miR-424-5p expression was 1.96 times higher in the case group, but miR-138 expression was 3.05 times lower in the plasma of OSCC patients. Conclusion: Our findings suggest that the evaluation of miR-138 and miR-424-5p expression in serum can be used as potent markers for carcinoma detection and also may be a potentially therapeutic approach in the future. Further longitudinal studies with larger samples are required to verify these findings. ]]>
p. 2185−2189
2476-762X
Vol.22/No.7
p. 2191−2198
2476-762X
Vol.22/No.7
p. 2199−2207
2476-762X
Vol.22/No.7
p. 2209−219
2476-762X
Vol.22/No.7
p. 2221−2236
2476-762X
Vol.22/No.7
p. 2237−2241
2476-762X
Vol.22/No.7
p. 2243−2249
2476-762X
Vol.22/No.7
p. 2251−2257
2476-762X
Vol.22/No.7
p. 2259−2265
2476-762X
Vol.22/No.7
p. 2267−2272
2476-762X
Vol.22/No.7
p. 2273−2278
2476-762X
Vol.22/No.7
p. 2279−2288
2476-762X
Vol.22/No.7
p. 2289−2294
2476-762X
Vol.22/No.7
p. 2295−2302
2476-762X
Vol.22/No.7
p. 2303−2310
2476-762X
Vol.22/No.7